Short Bowel Syndrome Market

DelveInsight’s ‘Short Bowel Syndrome–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Short Bowel Syndrome market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Short Bowel Syndrome symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Short Bowel Syndrome symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Short Bowel Syndrome Disease Understanding and Treatment Algorithm

Short Bowel Syndrome Overview

Short Bowel Syndrome is a congenital or acquired condition affecting the small intestine, hallmarked by loss of intestinal absorptive capacity with resultant malabsorption, dehydration, and malnutrition. This is due to the loss of absorptive surface area, as the human intestinal tract requires a massive surface area to absorb nutrients to support a growing and living organism effectively.


Short Bowel Syndrome is a challenging condition associated with significant morbidity and mortality, reduced quality of life, and high health care costs. In patients with Short Bowel Syndrome who are receiving long-term home parenteral nutrition (PN), 2–5 years survival rates have been reported to be up to 80% and 70%, respectively. Factors affecting survival with Short Bowel Syndrome include the anatomy and function of the remaining bowel, the patient's age, the primary disease process, comorbid diseases, the presence of chronic intestinal obstruction, and the experience of the management team.


Most commonly, Short Bowel Syndrome develops after surgical removal of a portion of the small intestine. This surgery is done to treat different types of intestinal conditions, like being born with a narrowed small intestine, or missing a portion of this part of the digestive system (intestinal atresia), injury to the intestines from physical trauma, sluggish movement within the intestines, cancer or cancer treatment that impacts the intestines, scarring of the intestines due to Crohn’s disease, causing obstruction in the digestive tract, and loss of blood flow to the intestines as a result of blood vessel blockage.


The main symptom of Short Bowel Syndrome is diarrhea—loose, watery stools. Diarrhea can lead to dehydration, malnutrition, and weight loss. Dehydration means the body lacks enough fluid and electrolytes—chemicals in salts, including sodium, potassium, and chloride—to work properly. Malnutrition is a condition that develops when the body does not get the right amount of vitamins, minerals, and nutrients it needs to maintain healthy tissues and organ function. Loose stools contain more fluid and electrolytes than solid stools. These problems can be severe and can be life-threatening without proper treatment.


Short Bowel Syndrome Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Short Bowel Syndrome market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Short Bowel Syndrome market report gives a thorough understanding of Short Bowel Syndrome symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Short Bowel Syndrome symptoms of treatment algorithms and treatment guidelines for Short Bowel Syndrome symptoms in the US, Europe, and Japan.

Short Bowel Syndrome Epidemiology

The epidemiology division’s Short Bowel Syndrome symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Short Bowel Syndrome epidemiology segmented as the Prevalent Cases of Short Bowel Syndrome, Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF), Age-specific Cases of Short Bowel Syndrome, Gender-specific Cases of Short Bowel Syndrome, Etiology-specific Cases. The report includes the prevalent Short Bowel Syndrome scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Short Bowel Syndrome Epidemiology

The epidemiology segment also provides the Short Bowel Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM prevalent cases of Short Bowel Syndrome were 34,713 cases in 2020.

Short Bowel Syndrome Drug Chapters

The drug chapter segment of the Short Bowel Syndrome report encloses the detailed analysis of Short Bowel Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Short Bowel Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Management of short bowel syndrome requires a multi-disciplinary approach that includes neonatologists, gastroenterologists, surgeons, nutritionists, pharmacists, nurses, and social workers. Guidelines have been set forth regarding the optimal Short Bowel Syndrome classification and management, but they must be taken in the context of the situation and cannot be used in every circumstance. Treatment includes Parenteral Nutrition and Enteral Nutrition and usually involves medications to help ease your signs and symptoms and increase the absorption rate.

Products detail in the report…


Short Bowel Syndrome Emerging Drugs

Glepaglutide is also known as ZP 1848—a long-acting glucagon-like peptide-2 (GLP-2) analog that was developed for patients with reduced or complete loss of intestinal function. Many people with Short Bowel Syndrome are dependent on the frequent intake of intravenous fluids and nutrition delivered through a central catheter. Currently, Glepaglutide is participating in Phase III clinical trial to determine the safety and efficacy of subcutaneous injection of the drug for the treatment of Short Bowel Syndrome.

Products detail in the report…

Short Bowel Syndrome Market Outlook

The Short Bowel Syndrome market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Short Bowel Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of Short Bowel Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Short Bowel Syndrome market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Short Bowel Syndrome market in 7MM. The market size of Short Bowel Syndrome in the seven major markets was USD 1720.5 million in 2020, and the market is estimated to increase at a CAGR of 5.82% for the study period (2018–2030).


The United States Market Outlook

This section provides a total of Short Bowel Syndrome market size and market size by therapies in the United States.


The United States accounts for the largest Short Bowel Syndrome market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Short Bowel Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Short Bowel Syndrome market size and market size by therapies in Japan are also mentioned.

Short Bowel Syndrome Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Short Bowel Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in the Phase II and Phase III stage. It also analyses Short Bowel Syndrome key players involved in developing targeted therapeutics.


Major players include Glepaglutide (Zealand Pharma), Apraglutide (VectivBio AG), and NM 002 (9 Meters Biopharma), being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Short Bowel Syndrome emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Short Bowel Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Short Bowel Syndrome market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Short Bowel Syndrome Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Short Bowel Syndrome, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Short Bowel Syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies Short Bowel Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Short Bowel Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Short Bowel Syndrome market

Report Highlights

  • In the coming years, Short Bowel Syndrome market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Short Bowel Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Short Bowel Syndrome. The launch of emerging therapies will significantly impact the Short Bowel Syndrome market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Short Bowel Syndrome.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Short Bowel Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Short Bowel Syndrome Pipeline Analysis
  • Short Bowel Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming therapies

Short Bowel Syndrome Report Key Strengths

  • 10 years Forecast
  • 7MM Coverage
  • Short Bowel Syndrome Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Short Bowel Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Short Bowel Syndrome Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Short Bowel Syndrome total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Short Bowel Syndrome market Size during the forecast period (2021–2030)?
  • At what CAGR, the Short Bowel Syndrome market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Short Bowel Syndrome market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Short Bowel Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Short Bowel Syndrome?
  • What is the historical Short Bowel Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Short Bowel Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Short Bowel Syndrome?
  • Out of all 7MM countries, which country would have the highest prevalent Short Bowel Syndrome population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Short Bowel Syndrome?
  • What are the current treatment guidelines for treating Short Bowel Syndrome in the USA, Europe, and Japan?
  • What are the Short Bowel Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Short Bowel Syndrome?
  • How many therapies are developed by each company for the treatment of Short Bowel Syndrome?
  • How many emerging therapies are in the mid-stage and late development stages to treat Short Bowel Syndrome?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Short Bowel Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Short Bowel Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Short Bowel Syndrome?
  • What are the global historical and forecasted markets of Short Bowel Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Short Bowel Syndrome market
  • To understand the future market competition in the Short Bowel Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Short Bowel Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Short Bowel Syndrome market
  • To understand the future market competition in the Short Bowel Syndrome market

1. Key Insights

2. Report Introduction

3. Short bowel syndrome Market Overview at a Glance

3.1. Market Share (%) Distribution of Short bowel syndrome in 2018

3.2. Market Share (%) Distribution of Short bowel syndrome in 2030

4. Executive Summary of Short Bowel Syndrome

5. Disease Background and Overview

5.1. Introduction

5.2. Causes

5.3. Symptoms

5.4. Clinical Features and Effect of Malabsorption

5.5. Complications of Short Bowel Syndrome

5.6. Diagnosis

5.7. Clinical Presentation of Infants with Short Bowel Syndrome

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Short Bowel Syndrome

7. Epidemiology of Short Bowel Syndrome

7.1. The United States

7.1.1. Prevalent Cases of Short Bowel Syndrome in the United States

7.1.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in the United States

7.1.3. Age-specific Cases of Short Bowel Syndrome in the United States

7.1.4. Gender-specific Cases of Short Bowel Syndrome in the United States

7.1.5. Etiology-specific Cases in the United States

7.2. EU5

7.3. Germany

7.3.1. Prevalent Cases of Short Bowel Syndrome in Germany

7.3.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Germany

7.3.3. Age-specific Cases of Short Bowel Syndrome in Germany

7.3.4. Gender-specific Cases of Short Bowel Syndrome in Germany

7.3.5. Etiology-specific Cases in Germany

7.4. France

7.4.1. Prevalent Cases of Short Bowel Syndrome in France

7.4.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in France

7.4.3. Age-specific Cases of Short Bowel Syndrome in France

7.4.4. Gender-specific Cases of Short Bowel Syndrome in France

7.4.5. Etiology-specific Cases in France

7.5. Italy

7.5.1. Prevalent Cases of Short Bowel Syndrome in Italy

7.5.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Italy

7.5.3. Age-specific Cases of Short Bowel Syndrome in Italy

7.5.4. Gender-specific Cases of Short Bowel Syndrome in Italy

7.5.5. Etiology-specific Cases in Italy

7.6. Spain

7.6.1. Prevalent Cases of Short Bowel Syndrome in Spain

7.6.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Spain

7.6.3. Age-specific Cases of Short Bowel Syndrome in Spain

7.6.4. Gender-specific Cases of Short Bowel Syndrome in Spain

7.6.5. Etiology-specific Cases in Spain

7.7. UK

7.7.1. Prevalent Cases of Short Bowel Syndrome in UK

7.7.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in UK

7.7.3. Age-specific Cases of Short Bowel Syndrome in UK

7.7.4. Gender-specific Cases of Short Bowel Syndrome in UK

7.7.5. Etiology-specific Cases in UK

7.8. Japan

7.8.1. Prevalent Cases of Short Bowel Syndrome in Japan

7.8.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (Short Bowel Syndrome-IF) in Japan

7.8.3. Age-specific Cases of Short Bowel Syndrome in Japan

7.8.4. Gender-specific Cases of Short Bowel Syndrome in Japan

7.8.5. Etiology-specific Cases in Japan

8. Organizations contributing towards Short Bowel Syndrome

9. Patient Journey

10. Case Reports

11. Treatment of Short Bowel Syndrome

11.1. Management of short bowel syndrome

11.2. Pharmacological interventions in Short Bowel Syndrome

11.3. Surgical management of Short Bowel Syndrome

12. Marketed Products

12.1. Gattex: Takeda

12.1.1. Product Description

12.1.2. Regulatory Milestones

12.1.3. Safety and Efficacy

12.1.4. Product Profile

13. Emerging Products

13.1. Glepaglutide: Zealand Pharma

13.1.1. Drug Descriptions

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Clinical Trials Information

13.1.5. Safety and Efficacy

13.1.6. Product Profile

13.2. Apraglutide: VectivBio AG

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Product Profile

13.3. NM 002: 9 Meters Biopharma

13.3.1. Drug Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Clinical Trials Information

13.3.5. Safety and Efficacy

13.3.6. Product Profile

14. Short Bowel Syndrome: 7 Major Market Analysis

14.1. Key Findings

14.2. Market Size of Short Bowel Syndrome in 7MM

15. Market Outlook

15.1. United States Market Size

15.1.1. Total Market Size of Short bowel syndrome in United States

15.1.2. Market Size of Short bowel syndrome by Therapies in United States

15.2. EU-5 Market Size

15.3. Germany

15.3.1. Total Market size of Short bowel syndrome in Germany

15.3.2. Market Size of Short bowel syndrome by Therapies in Germany

15.4. France

15.4.1. Total Market size of Short bowel syndrome in France

15.4.2. Market Size of Short bowel syndrome by Therapies in France

15.5. Italy

15.5.1. Total Market size of Short bowel syndrome in Italy

15.5.2. Market Size of Short bowel syndrome by Therapies in Italy

15.6. Spain

15.6.1. Total Market size of Short bowel syndrome in Spain

15.6.2. Market Size of Short bowel syndrome by Therapies in Spain

15.7. United Kingdom

15.7.1. Total Market size of Short bowel syndrome in United Kingdom

15.7.2. Market Size of Short bowel syndrome by Therapies in United Kingdom

15.8. Japan

15.8.1. Total Market size of Short bowel syndrome in Japan

15.8.2. Market Size of Short bowel syndrome by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Appendix

21. Bibliography

22. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Summary of Short Bowel Syndrome, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Prevalent Patient Population of Short Bowel Syndrome in 7MM (2018–2030)

Table 3: Prevalent Cases of Short Bowel Syndrome in the United States (2018–2030)

Table 4: Prevalent Cases of Short Bowel Syndrome-IF in the United States (2018–2030)

Table 5: Age-specific Cases of Short Bowel Syndrome in the United States (2018–2030)

Table 6: Gender-specific Cases of Short Bowel Syndrome in the United States (2018–2030)

Table 7: Etiology-specific Cases in the United States (2018–2030)

Table 8: Prevalent Cases of Short Bowel Syndrome in Germany (2018–2030)

Table 9: Prevalent Cases of Short Bowel Syndrome-IF in Germany (2018–2030)

Table 10: Age-specific Cases of Short Bowel Syndrome in Germany (2018–2030)

Table 11: Gender-specific Cases of Short Bowel Syndrome in Germany (2018–2030)

Table 12: Etiology-specific Cases in Germany (2018–2030)

Table 13: Prevalent Cases of Short Bowel Syndrome in France (2018–2030)

Table 14: Prevalent Cases of Short Bowel Syndrome-IF in France (2018–2030)

Table 15: Age-specific Cases of Short Bowel Syndrome in France (2018–2030)

Table 16: Gender-specific Cases of Short Bowel Syndrome in France (2018–2030)

Table 17: Etiology-specific Cases in France (2018–2030)

Table 18: Prevalent Cases of Short Bowel Syndrome in Italy (2018–2030)

Table 19: Prevalent Cases of Short Bowel Syndrome-IF in Italy (2018–2030)

Table 20: Age-specific Cases of Short Bowel Syndrome in Italy (2018–2030)

Table 21: Gender-specific Cases of Short Bowel Syndrome in Italy (2018–2030)

Table 22: Etiology-specific Cases in Italy (2018–2030)

Table 23: Prevalent Cases of Short Bowel Syndrome in Spain (2018–2030)

Table 24: Prevalent Cases of Short Bowel Syndrome-IF in Spain (2018–2030)

Table 25: Age-specific Cases of Short Bowel Syndrome in Spain (2018–2030)

Table 26: Gender-specific Cases of Short Bowel Syndrome in Spain (2018–2030)

Table 27: Etiology-specific Cases in Spain (2018–2030)

Table 28: Prevalent Cases of Short Bowel Syndrome in UK (2018–2030)

Table 29: Prevalent Cases of Short Bowel Syndrome-IF in UK (2018–2030)

Table 30: Age-specific Cases of Short Bowel Syndrome in UK (2018–2030)

Table 31: Gender-specific Cases of Short Bowel Syndrome in UK (2018–2030)

Table 32: Etiology-specific Cases in UK (2018–2030)

Table 33: Prevalent Cases of Short Bowel Syndrome in Japan (2018–2030)

Table 34: Prevalent Cases of Short Bowel Syndrome-IF in Japan (2018–2030)

Table 35: Age-specific Cases of Short Bowel Syndrome in Japan (2018–2030)

Table 36: Gender-specific Cases of Short Bowel Syndrome in Japan (2018–2030)

Table 37: Etiology-specific Cases in Japan (2018–2030)

Table 38: Organizations contributing towards Short Bowel Syndrome

Table 39: Glepaglutide, Clinical Trial Description, 2021

Table 40: Apraglutide, Clinical Trial Description, 2021

Table 41: NM 002, Clinical Trial Description, 2021

Table 42: 7 Major Market Size of Short Bowel Syndrome in USD Million (2018–2030)

Table 43: United States Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 44: United States Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 45: Germany Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 46: Germany Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 47: France Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 48: France Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 49: Italy Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 50: Italy Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 51: Spain Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 52: Spain Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 53: United Kingdom Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 54: United Kingdom Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Table 55: Japan Market Size of Short bowel syndrome in USD Million (2018–2030)

Table 56: Japan Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Spectrum of Short Bowel Syndrome ranging from intestinal insufficiency to intestinal failure

Figure 2: Clinical features of short bowel syndrome can be predicted based on the gastrointestinal region(s) lost to surgical resection and resulting physiological changes

Figure 3: Prevalent Population of Short Bowel Syndrome in 7MM (2018–2030)

Figure 4: Prevalent Cases of Short Bowel Syndrome in the United States (2018–2030)

Figure 5: Prevalent Cases of Short Bowel Syndrome-IF in the United States (2018–2030)

Figure 6: Age-specific Cases of Short Bowel Syndrome in the United States (2018–2030)

Figure 7: Gender-specific Cases of Short Bowel Syndrome in the United States (2018–2030)

Figure 8: Etiology-specific Cases in the United States (2018–2030)

Figure 9: Prevalent Cases of Short Bowel Syndrome in Germany (2018–2030)

Figure 10: Prevalent Cases of Short Bowel Syndrome-IF in Germany (2018–2030)

Figure 11: Age-specific Cases of Short Bowel Syndrome in Germany (2018–2030)

Figure 12: Gender-specific Cases of Short Bowel Syndrome in Germany (2018–2030)

Figure 13: Etiology-specific Cases in Germany (2018–2030)

Figure 14: Prevalent Cases of Short Bowel Syndrome in France (2018–2030)

Figure 15: Prevalent Cases of Short Bowel Syndrome-IF in France (2018–2030)

Figure 16: Age-specific Cases of Short Bowel Syndrome in France (2018–2030)

Figure 17: Gender-specific Cases of Short Bowel Syndrome in France (2018–2030)

Figure 18: Etiology-specific Cases in France (2018–2030)

Figure 19: Prevalent Cases of Short Bowel Syndrome in Italy (2018–2030)

Figure 20: Prevalent Cases of Short Bowel Syndrome-IF in Italy (2018–2030)

Figure 21: Age-specific Cases of Short Bowel Syndrome in Italy (2018–2030)

Figure 22: Gender-specific Cases of Short Bowel Syndrome in Italy (2018–2030)

Figure 23: Etiology-specific Cases in Italy (2018–2030)

Figure 24: Prevalent Cases of Short Bowel Syndrome in Spain (2018–2030)

Figure 25: Prevalent Cases of Short Bowel Syndrome-IF in Spain (2018–2030)

Figure 26: Age-specific Cases of Short Bowel Syndrome in Spain (2018–2030)

Figure 27: Gender-specific Cases of Short Bowel Syndrome in Spain (2018–2030)

Figure 28: Etiology-specific Cases in Spain (2018–2030)

Figure 29: Prevalent Cases of Short Bowel Syndrome in UK (2018–2030)

Figure 30: Prevalent Cases of Short Bowel Syndrome-IF in UK (2018–2030)

Figure 31: Age-specific Cases of Short Bowel Syndrome in UK (2018–2030)

Figure 32: Gender-specific Cases of Short Bowel Syndrome in UK (2018–2030)

Figure 33: Etiology-specific Cases in UK (2018–2030)

Figure 34: Prevalent Cases of Short Bowel Syndrome in Japan (2018–2030)

Figure 35: Prevalent Cases of Short Bowel Syndrome-IF in Japan (2018–2030)

Figure 36: Age-specific Cases of Short Bowel Syndrome in Japan (2018–2030)

Figure 37: Gender-specific Cases of Short Bowel Syndrome in Japan (2018–2030)

Figure 38: Etiology-specific Cases in Japan (2018–2030)

Figure 39: 7 Major Market Size of Short Bowel Syndrome in USD Million (2018–2030)

Figure 40: Market Size of Short bowel syndrome in the United States, USD Million (2018–2030)

Figure 41: The United States Market Size of Short bowel syndrome by Therapies in USD Million

Figure 42: Market Size of Short bowel syndrome in the Germany, USD Million (2018–2030)

Figure 43: The Germany Market Size of Short bowel syndrome by Therapies in USD Million

Figure 44: Market Size of Short bowel syndrome in the France, USD Million (2018–2030)

Figure 45: The France Market Size of Short bowel syndrome by Therapies in USD Million

Figure 46: Market Size of Short bowel syndrome in the Italy, USD Million (2018–2030)

Figure 47: The Italy Market Size of Short bowel syndrome by Therapies in USD Million

Figure 48: Market Size of Short bowel syndrome in the Spain, USD Million (2018–2030)

Figure 49: The Spain Market Size of Short bowel syndrome by Therapies in USD Million

Figure 50: Market Size of Short bowel syndrome in the United Kingdom, USD Million (2018–2030)

Figure 51: The United Kingdom Market Size of Short bowel syndrome by Therapies in USD Million

Figure 52: Market Size of Short bowel syndrome in the Japan, USD Million (2018–2030)

Figure 53: The Japan Market Size of Short bowel syndrome by Therapies in USD Million (2018–2030)

Takeda

Zealand Pharma

VectivBio AG

9 Meters Biopharma

  • Tags:
  • Short Bowel Syndrome market
  • Short Bowel Syndrome market resear...
  • Short Bowel Syndrome market insigh...
  • Short Bowel Syndrome market trends
  • Short Bowel Syndrome market foreca...
  • Short Bowel Syndrome market share
  • Short Bowel Syndrome pipeline drug...
  • Short Bowel Syndrome treatment alg...
  • Short Bowel Syndrome drugs
  • Short Bowel Syndrome sales forecas...
  • Short Bowel Syndrome market size
  • Short Bowel Syndrome disease
  • Short Bowel Syndrome epidemiology
  • Short Bowel Syndrome

Forward to Friend

Need A Quote